欢迎访问《中国临床药理学与治疗学》杂志官方网站，今天是

中国临床药理学与治疗学 ›› 2025, Vol. 30 ›› Issue (6): 849-857.doi: 10.12092/j.issn.1009-2501.2025.06.015

• 综述与讲座 • 上一篇    下一篇

可切除性高危恶性黑素瘤的（新）辅助治疗研究进展

杨永婷1，2，3，4，韩舒欣1，康晓静2，3，4   

  1. 1新疆大学生命科学与技术学院，新疆生物资源与基因工程重点实验室，乌鲁木齐  830046，新疆；2新疆维吾尔自治区人民医院皮肤性病科，乌鲁木齐  830001，新疆；3新疆皮肤性病临床医学研究中心，乌鲁木齐  830001，新疆；4新疆皮肤病研究重点实验室，乌鲁木齐  830001，新疆

  • 收稿日期:2024-09-11 修回日期:2024-11-07 出版日期:2025-06-26 发布日期:2025-06-09
  • 通讯作者: 康晓静，女，博士，教授，主任医师，研究方向：皮肤肿瘤。 E-mail： drkangxj666@163.com
  • 作者简介:杨永婷，女，博士，研究方向：皮肤肿瘤。 E-mail： 17509071909@163.com
  • 基金资助:
    新疆维吾尔自治区“天山英才”培养计划（2022TSYCLJ0025）

Advances in (neo) adjuvant therapy for resectable high-risk malignant melanoma

YANG Yongting1,2,3,4, HAN Shuxin1, KANG Xiaojing2,3,4   

  1. 1 Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, Colege of Life Science &Technology,Xinjiang University, Urumqi 830046, Xinjiang, China; 2 Department of Dermatology and Venereology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, Xinjiang, China; 3 Xinjiang Clinical Research Center for Dermatology and Venereology, Urumqi 830001, Xinjiang, China; 4 Xinjiang Key Laboratory of Dermatology Research, Urumqi 830001, Xinjiang, China
  • Received:2024-09-11 Revised:2024-11-07 Online:2025-06-26 Published:2025-06-09

PDF (PC)

242

摘要：

恶性黑素瘤是皮肤癌中恶性程度较高的肿瘤，目前外科手术仍为大多数患者的首选治疗方法，但仅接受手术的高危黑素瘤患者的5年无病生存率只有40%～60%，术前术后（新）辅助治疗可降低高危手术患者的复发率、提高存活率，因此近几年有关黑素瘤的（新）辅助治疗包括放疗、生物化学治疗、免疫治疗、靶向治疗被广泛研究。本文对近年来可切除的高危黑素瘤患者（新）辅助治疗的相关研究进行回顾与总结，以期为其提供合适的（新）辅助治疗方案，进而改善生存及预后。

关键词: 黑素瘤, 放疗, 生物化学治疗, 免疫治疗, 靶向治疗

Abstract:

Malignant melanoma represents a highly aggressive form of skin cancer. At present, surgical resection remains the primary treatment modality for the majority of patients diagnosed with this condition. However, the five-year disease-free survival rate for high-risk melanoma patients undergoing surgery alone ranges from 40% to 60%. The implementation of preoperative and postoperative (neo) adjuvant therapies has been demonstrated to diminish recurrence rates and improve survival outcomes for high-risk surgical patients. Consequently, various (neo) adjuvant treatments for melanoma-including radiotherapy, biochemotherapy, immunotherapy, and targeted therapy-have been the subject of extensive research in recent years. This review aims to summarize the latest advancements in (neo) adjuvant therapies for resectable high-risk melanoma patients, with the objective of providing an effective (neo) adjuvant therapy strategy that may improve patient survival and overall prognosis.

Key words: melanoma, radiotherapy, biochemotherapy, immunotherapy, target therapy

中图分类号: 

版权所有 © 《中国临床药理学与治疗学》编辑部
地址：安徽省芜湖市皖南医学院弋矶山医院内　邮编：241001
电话：0553-5738350　 传真：0553- 5738350　 Email：cjcpt96@163.com
本系统由北京玛格泰克科技发展有限公司设计开发